Aghi M - Search Results

1

Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors.

Aghi M, Chiocca EA. Aghi M, et al. Mol Ther. 2005 Dec;12(6):994-1005. doi: 10.1016/j.ymthe.2005.07.693. Epub 2005 Aug 30. Mol Ther. 2005. PMID: 16137927 Free article. Review.

2

Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.

Kramm CM, Chase M, Herrlinger U, Jacobs A, Pechan PA, Rainov NG, Sena-Esteves M, Aghi M, Barnett FH, Chiocca EA, Breakefield XO. Kramm CM, et al. Among authors: aghi m. Hum Gene Ther. 1997 Nov 20;8(17):2057-68. doi: 10.1089/hum.1997.8.17-2057. Hum Gene Ther. 1997. PMID: 9414254

3

Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies.

Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Aghi M, et al. J Natl Cancer Inst. 1998 Mar 4;90(5):370-80. doi: 10.1093/jnci/90.5.370. J Natl Cancer Inst. 1998. PMID: 9498487

4

Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies.

Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA. Aghi M, et al. Cancer Res. 1999 Aug 15;59(16):3861-5. Cancer Res. 1999. PMID: 10463570

5

Genetically engineered herpes simplex viral vectors in the treatment of brain tumors: a review.

Aghi M, Chiocca EA. Aghi M, et al. Cancer Invest. 2003 Apr;21(2):278-92. doi: 10.1081/cnv-120016423. Cancer Invest. 2003. PMID: 12743992 Review. No abstract available.

6

Viral therapy for glioblastoma.

Chiocca EA, Aghi M, Fulci G. Chiocca EA, et al. Among authors: aghi m. Cancer J. 2003 May-Jun;9(3):167-79. doi: 10.1097/00130404-200305000-00005. Cancer J. 2003. PMID: 12952302 Review.

7

Gene therapy for glioblastoma.

Aghi M, Chiocca EA. Aghi M, et al. Neurosurg Focus. 2006 Apr 15;20(4):E18. Neurosurg Focus. 2006. PMID: 16709023 Review.

8

Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes.

Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. Aghi M, et al. Cancer Res. 2006 Sep 15;66(18):9054-64. doi: 10.1158/0008-5472.CAN-05-3759. Cancer Res. 2006. PMID: 16982747

9

Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16.

Aghi M, Visted T, Depinho RA, Chiocca EA. Aghi M, et al. Oncogene. 2008 Jul 10;27(30):4249-54. doi: 10.1038/onc.2008.53. Epub 2008 Mar 17. Oncogene. 2008. PMID: 18345032 Free PMC article.

10

Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication.

Aghi MK, Chiocca EA. Aghi MK, et al. Mol Ther. 2009 Jan;17(1):8-9. doi: 10.1038/mt.2008.275. Mol Ther. 2009. PMID: 19116635 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

359 results

Search Page

Filters